iCell Gene Therapeutics is proud to announce the publication of our preclinical CD4CAR T-cell data in Leukemia, a leading hematology-oncology journal. In our article, "Preclinical targeting of human T cell malignancies using CD4-specific chimeric antigen receptor (CAR)-engineered T cells" we demonstrate the efficacy of our CAR technology for the targeting of human CD4 positive T-cell malignancies in blood samples obtained from patients with currently incurable disease. Our study is unique in that it is among the first CAR therapy studies focused on T-cell malignancies, a subset of cancers with poor prognosis and few treatment options for many patients. We are grateful for the opportunity to contribute to the science of CAR therapy, with the long-term goal of enhanced patient outcomes. As a result of our research team’s findings, we are now one step closer to bringing curative CAR therapy to patients with relapsing or resistant T-cell malignancies. Read more about it here.